Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies
Cancer Cell · 2023-12 · 41 (12) · 2136-2153.e13
DOI: 10.1016/j.ccell.2023.11.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-12. Verfasst von Luciano Nicosia und 22 weiteren Autor:innen. Beteiligte Einrichtung: Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK. Hauptthemen laut MEDLINE: Nuclear Proteins, Hematologic Neoplasms. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Blood Cancer UK, Leukaemia UK.
Abstract (Originalsprache)
CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP from an enhancer subset marked by strong MYB occupancy and high H3K27 acetylation, with downregulation of the subordinate oncogenic network and redistribution to sites close to differentiation genes. In myeloma cells, CCS1477 induces eviction of EP300/CBP from FGFR3, the target of the common (4; 14) translocation, with redistribution away from IRF4-occupied sites to TCF3/E2A-occupied sites. In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in heavily pre-treated multiple myeloma. In vivo preclinical combination studies reveal synergistic responses to treatment with standard-of-care agents. Thus, CCS1477 exhibits encouraging preclinical and early-phase clinical activity by disrupting recruitment of EP300/CBP to enhancer networks occupied by critical transcription factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK.
- CellCentric Ltd., Cambridge CB10 1XL, UK.
- Epigenetics of Haematopoiesis Group, The University of Manchester, Manchester M20 4BX, UK.
- Western General Hospital, Edinburgh EH4 2XU, UK.
- The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
- Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0YN, UK.
Förderung
- Cancer Research UK
- Blood Cancer UK
- Leukaemia UK
Zitieren
APA
Nicosia, L., Spencer, G. J., Brooks, N., Amaral, F. M. R., Basma, N. J., Chadwick, J. A., Revell, B., Wingelhofer, B., Maiques-Diaz, A., Sinclair, O., Camera, F., Ciceri, F., Wiseman, D. H., Pegg, N., West, W., Knurowski, T., Frese, K., Clegg, K., Campbell, V. L., …, & Somervaille, T. C. P. (2023). Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell, 41(12), 2136-2153.e13. https://doi.org/10.1016/j.ccell.2023.11.001
Vancouver
Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, et al. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 2023;41(12):2136-2153.e13. doi:10.1016/j.ccell.2023.11.001
BibTeX
@article{Nicosia2023,
author = {Nicosia, Luciano and Spencer, Gary J and Brooks, Nigel and Amaral, Fabio M R and Basma, Naseer J and Chadwick, John A and Revell, Bradley and Wingelhofer, Bettina and Maiques-Diaz, Alba and Sinclair, Oliver and Camera, Francesco and Ciceri, Filippo and Wiseman, Daniel H and Pegg, Neil and West, Will and Knurowski, Tomasz and Frese, Kris and Clegg, Karen and Campbell, Victoria L and Cavet, James and Copland, Mhairi and Searle, Emma and Somervaille, Tim C P},
title = {Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {12},
pages = {2136--2153.e13},
doi = {10.1016/j.ccell.2023.11.001}
}
EUVIMED